What safety concerns relate to the gene therapy approach to vascular retinal diseases?

Click here to read the Cover Story, "Strategies for sustained anti-VEGF delivery aimed at consistent dosing, durability."

There are long-term concerns about gene therapy for a number of reasons.
First, across the disease stages, there are various levels of anti-VEGF needed. Although age-related macular degeneration appears to be a chronic condition, a small percentage but significant number of patients do not need chronic therapy and can be managed with a low number of injections.
In the CATT trial, 14% of patients on average received one or two injections over a 2-year (Read more...)

Full Story →